Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Fulvestrant*/adverse effects ; Data Mining* ; Adverse Drug Reaction Reporting Systems*/statistics & numerical data ; United States Food and Drug Administration* ; Databases, Factual*; Humans ; Female ; Middle Aged ; Adult ; Aged ; United States ; Breast Neoplasms/drug therapy ; Risk Factors ; Antineoplastic Agents, Hormonal/adverse effects ; Adolescent ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Young Adult

Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant. To perform data mining on adverse events (AEs) associated with fulvestrant and explore the risk factors contributing to severe AEs, providing a reference for the rational use of fulvestrant in clinical practice. Retrieved adverse event report information associated with fulvestrant from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, covering the period from market introduction to September 30, 2023. Suspicious AEs were screened using the reporting odds ratio (ROR) and proportional reporting ratio methods based on disproportionality analysis. Univariate and multivariate logistic regression analyses were conducted on severe AEs to explore the risk factors associated with fulvestrant-induced severe AEs. A total of 6947 reports related to AEs associated with fulvestrant were obtained, including 5924 reports of severe AEs and 1023 reports of non-severe AEs. Using the disproportionality analysis method, a total of 210 valid AEs were identified for fulvestrant, with 45 AEs (21.43%) not listed in the product labeling, involving 11 systems and organs. The AEs associated with fulvestrant were sorted by frequency of occurrence, with neutropenia (325 cases) having the highest number of reports. By signal strength, injection site pruritus showed the strongest signal (ROR = 658.43). The results of the logistic regression analysis showed that concurrent use of medications with extremely high protein binding (≥ 98%) is an independent risk factor for severe AEs associated with fulvestrant. Age served as a protective factor for fulvestrant-related AEs. The co-administration of fulvestrant with CYP3A4 enzyme inhibitors did not show statistically significant correlation with the occurrence of severe AEs. Co-administration of drugs with extremely high protein binding (≥ 98%) may increase the risk of severe adverse reactions of fulvestrant. Meanwhile, age (60-74 years) may reduce the risk of severe AEs of fulvestrant. However, further clinical research is still needed to explore and verify whether there is interaction between fulvestrant and drugs with high protein binding through more clinical studies.
(© 2024. The Author(s).)

Breast Cancer Res Treat. 2020 Apr;180(2):359-368. (PMID: 32030569)
Drug Saf. 2006;29(10):875-87. (PMID: 16970511)
Ann Pharmacother. 2006 Sep;40(9):1572-83. (PMID: 16912252)
Zhonghua Yi Xue Za Zhi. 2023 Oct 17;103(38):2993-3001. (PMID: 37813650)
Cancer Treat Rev. 2022 Sep;109:102432. (PMID: 35839531)
Sci Rep. 2021 Feb 19;11(1):4274. (PMID: 33608590)
Br J Clin Pharmacol. 1994 Feb;37(2):125-8. (PMID: 8186058)
Int J Med Sci. 2013 Apr 25;10(7):796-803. (PMID: 23794943)
Clin Pharmacol Ther. 2024 Feb;115(2):256-268. (PMID: 37994531)
Clin Cancer Res. 2017 Aug 1;23(15):4046-4054. (PMID: 28280092)
Cancer Treat Rev. 2023 Jun;117:102569. (PMID: 37146385)
Cancer. 2000 Aug 15;89(4):817-25. (PMID: 10951345)
Breast Cancer Res. 2016 Aug 04;18(1):79. (PMID: 27492244)
JMA J. 2022 Oct 17;5(4):416-426. (PMID: 36407064)
An Bras Dermatol. 2019 Mar-Apr;94(2):218-220. (PMID: 31090829)
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766)
Cancer Res. 2001 Sep 15;61(18):6739-46. (PMID: 11559545)
Front Oncol. 2023 Oct 06;13:1276976. (PMID: 37869095)
Pharmaceuticals (Basel). 2021 Jul 26;14(8):. (PMID: 34451816)
Cancers (Basel). 2021 Aug 25;13(17):. (PMID: 34503097)
Br J Dermatol. 2015 Nov;173(5):1250-4. (PMID: 26769645)
Oncologist. 2002;7(6):477-80. (PMID: 12490735)
Front Pharmacol. 2020 Apr 24;11:505. (PMID: 32390847)
Front Pharmacol. 2023 Nov 01;14:1225919. (PMID: 38027014)
Oncologist. 2023 Jan 18;28(1):23-32. (PMID: 36239405)
J Pharm Pract. 2022 Dec;35(6):1034-1038. (PMID: 33910404)

2023YD064 Yantai Science and Technology Bureau; D202313017815 Hunan Provincial Health Commission Project

Keywords: Adverse events; Data mining; FAERS; Fulvestrant; Pharmacovigilance; Real-world

Date Created: 20240518 Date Completed: 20240518 Latest Revision: 20240521

20240521

PMC11102440

10.1038/s41598-024-62238-1

38762547